Furthermore, in vivo experiments showed that, compared with HT29 WT tumors, HDGF KO significantly reduced tumor volume and weight, and enhanced sensitivity to 5-FU or oxaliplatin (Figure 6A–D). This evidence concerns the gene HDGF and neoplasm.